ArticleJournal of biomedical optics2025
Imaging protoporphyrin IX photoproduct accumulation as a dosimetry reporter for monitoring photodynamic therapy of oral cancer.
Article in Journal of biomedical optics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mesoscopic Fluorescence Imaging of Light-Triggered Chemotherapeutic Release in Cancer Spheroid Models.Pharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Significance: Photodynamic therapy (PDT) for the treatment of oral cancers and oral potentially malignant lesions can be enhanced by the capability of the photosensitizer to serve as a fluorescence contrast agent for treatment guidance. The development of image-based dosimetry reporters can inform treatment progress in real time to avoid under-treatment, leading to incomplete response and recurrence. Aim: We investigate the hypothesis that imaging of protoporphyrin IX (PpIX) photoproduct (PP) accumulation may be leveraged as an implicit PDT dosimetry reporter for PDT using 5-aminolevulinic acid (ALA)-induced PpIX photosensitization. Approach: In initial spectroscopy studies, we investigate dose-dependent changes in absorption and fluorescence spectra of PpIX corresponding to PP accumulation during red light (635 nm) delivery. We use spectral analysis to select fluorescence excitation and spectral filtering components for PP imaging during treatment. We evaluate the capability for imaging PP accumulation concomitant with PpIX photobleaching in tissue phantoms, 3D oral squamous cell carcinoma (OSCC) models, and in murine xenografts. Results: Spectroscopy shows fluence-dependent changes in PpIX optical properties, and that excitation of photobleached PpIX with 450 nm light produces fluorescence emission associated with PpIX PPs. An existing handheld intraoral probe is shown to be capable of imaging dose-dependent PP accumulation with the addition of a spectral filter to isolate fluorescence emission longer than 650 nm. PP signal increases concomitant with PpIX photobleaching in a fluence-dependent manner and correlates with the extent of cytotoxic response in 3D cultures. PP accumulation is also observed to occur concomitantly with photobleaching in OSCC subcutaneous xenografts. Conclusions: Overall, the results show that imaging of PP accumulation is feasible by adapting traditional photodiagnosis optical components and may serve as a dosimetry reporter for ALA-PDT, which is complementary to the measurement of PpIX photobleaching.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.